Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib
Paul Dent, Laurence Booth, Andrew Poklepovic, Daniel D. Von Hoff, Jennifer Martinez, Yong Zhou, John F. Hancock
Topics & Concepts
NeratinibAfatinibCancer researchBiologyErbBCell biologyPhosphorylationOsimertinibMolecular biologyEpidermal growth factor receptorGefitinibSignal transductionBiochemistryErlotinibCancerReceptorTrastuzumabBreast cancerGeneticsHippo pathway signaling and YAP/TAZPI3K/AKT/mTOR signaling in cancerPhagocytosis and Immune Regulation